<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and <z:chebi fb="0" ids="2038">azacitidine</z:chebi> for higher risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease </plain></SENT>
</text></document>